A compelling value story needs a strong product portfolio at its core. But that’s easier said than done, with patent cliffs, rising R&D costs, intense competition, and increasing pricing pressures. Mergers and acquisitions present both opportunities and risks, as high deal values can be difficult to justify, and expected returns can be difficult to realize.

While leading R&D capabilities and a disciplined approach to L&A are essential, well-informed strategies and decision processes are at the heart of developing a robust portfolio. Understanding established and emerging market needs will be increasingly important, and organizations will need to incorporate economic and clinical value considerations early on — for every molecule in the pipeline and every potential acquisition. With the right insight, pharmaceutical executives can focus their resources on bringing the most valuable innovations to market.

Numerof can help you focus your efforts on the most valuable opportunities and innovations. Explore our solutions for your industry.